Lytix Biopharma

LTX-109

A NOVEL ANTIMICROBIAL PRODUCT

FOR TOPICAL TREATMENT OF SKIN INFECTIONS

A PHASE II ASSET WITH OUTSTANDING EFFICACY

COMPARED TO MARKETED GOLD-STANDARD DRUGS

LTX-109 product highlights

- √ **Novel mechanism of action**
  - √ ***Ultra-rapid, bactericidal***
- √ **Broad spectrum of activity**
  - √ ***Gram+ bacteria***
  - √ ***Gram - bacteria***
  - √ ***Yeasts and fungi***
- √ **Low propensity for resistance development**
- √ **Active against drug-resistant strains**
- √ **Effective against fungal and bacterial biofilms**
- √ **Superior efficacy compared to market leaders**



Lytix Biopharma has invented and secured broadly defined rights to a new class of low-molecular weight analogues of innate immunity membrane-active host defence peptides. LTX-109 has completed phase I/II studies in nasal decolonisation of MRSA/MSSA and uncomplicated, Gram(+) skin infections, and is currently in a Phase II PoC study in impetigo.

Bactericidal kill-kinetics

LTX-109 is a novel antimicrobial agent with a membrane lysing mode of action. By mimicking the properties of innate antimicrobial peptides, biological properties can be designed into a small drug molecule.

In vitro kill kinetics against *Staphylococcus aureus*



A NOVEL ANTIMICROBIAL PRODUCT

FOR TOPICAL TREATMENT OF SKIN INFECTIONS

Lack of resistance development

In general, compounds acting on the cell membrane have low propensity for developing resistance. The occurrence of spontaneous resistance towards LTX-109 was studied by plating a heterogeneous mixture of bacteria. Neither in wild-type, MRSA nor glycopeptide-resistant *Staphylococcus arueus* was any spontaneous resistance observed. No signs of resistance development have been observed in 5 different *Staphylococcus aureus* strains after 14 passages.

In vitro test of resistance development in *Staphylococcus aureus*



Outstanding efficacy in animal models

In vivo efficacy has been investigated at Statens Serum Institut (SSI) in Copenhagen, Denmark, and NAEJA, Canada, using a well-documented skin infection model.

A skin lesion is infected on day one, and the infection allowed to develop for 24 hours. The drug and comparators are applied 3 times in a single day. LTX-109 is strongly bactericidal against all strains of *Staphylococci* tested, including both hospital-acquired and community -acquired MRSA (USA300).

In vivo bactericidal effect against wild-type *Staphylococcus aureus*



Market Opportunities

- Skin infections
- Nasal MRSA decolonisation
- Infected ulcers/ wounds
- Localized fungal infections

In vivo bactericidal effect against MRSA



Contact details:

Anders Fugelli, PhD

Head of Business Development

anders.fugelli@lytixbiopharma.com

+47 924 81 432

Lytix Biopharma